In a filing, TG Therapeutics Inc revealed its CFO Power Sean A unloaded Company’s shares for reported $0.34 million on Jan 03 ’25. In the deal valued at $30.29 per share,11,337 shares were sold. As a result of this transaction, Power Sean A now holds 670,632 shares worth roughly $18.78 million.
Then, Power Sean A sold 10,021 shares, generating $285,939 in total proceeds. Upon selling the shares at $28.53, the CFO now owns 660,611 shares.
Before that, Power Sean A bought 10,021 shares. TG Therapeutics Inc shares valued at $285,941 were divested by the Officer at a price of $28.53 per share.
TD Cowen initiated its TG Therapeutics Inc [TGTX] rating to a Buy in a research note published on October 29, 2024; the price target was $50. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in early August from “a Sell” to “a Neutral”. BofA Securities started covering the stock on May 20, 2022. It rated TGTX as “an Underperform”.
Price Performance Review of TGTX
On Tuesday, TG Therapeutics Inc [NASDAQ:TGTX] saw its stock unchanged to $28.00. Over the last five days, the stock has lost -10.96%. TG Therapeutics Inc shares have fallen nearly -6.98% since the year began. Nevertheless, the stocks have risen 42.49% over the past one year. While a 52-week high of $36.84 was reached on 01/02/25, a 52-week low of $12.84 was recorded on 01/07/25. SMA at 50 days reached $30.82, while 200 days put it at $22.17.
Levels Of Support And Resistance For TGTX Stock
The 24-hour chart illustrates a support level at 27.37, which if violated will result in even more drops to 26.73. On the upside, there is a resistance level at 28.83. A further resistance level may holdings at 29.65. The Relative Strength Index (RSI) on the 14-day chart is 37.84, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.11%. Stochastics %K at 5.22% indicates the stock is a buying.
How much short interest is there in TG Therapeutics Inc?
A steep rise in short interest was recorded in TG Therapeutics Inc stocks on 2024-12-13, dropping by -1.19 million shares to a total of 27.14 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 28.33 million shares. There was a decline of -4.38%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 23, 2022 when B. Riley Securities resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $35.
